Supporting information on the proposal to amend access criteria for type 2 diabetes medicines

On this page, you will find the information relating to Pharmac and our Board's consideration of the this proposal.

Board papers

Economic information

Factors for consideration

Summary of Pharmac's consideration of the Factors for Consideration for SGLT2i and GLP-1 [PDF, 251 KB]

We use summaries like these as part of the prioritisation process. This is a summary prepared by our health economists using the information from the Technology Assessment Report.

Technology Assessment Report (TAR)

TAR reports are developed by our health economists so we can understand all the costs and benefits of a treatment, including the financial and health costs. 

Excerpt from the Technology Assessment Report (TAR) for SGLT2 inhibitors for type 2 diabetes mellitus (T2DM) with cardiovascular disease (CVD) risk greater than 10% [PDF, 916 KB]

Budget impact analysis

These are the spreadsheets we use to try to understand how many people may be affected by our decision and what things may cost. 

December 2025 Budget impact summary (base case) [XLSX, 3.5 MB]

March 2026 Budget impact summary [XLSX, 3 MB]